Choi SH

References (41)

Title : Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea - Lee_2023_Naunyn.Schmiedebergs.Arch.Pharmacol__1
Author(s) : Lee JH , Kanwar B , Khattak A , Altschuler E , Sergi C , Lee SJ , Choi SH , Park J , Coleman M , Bourbeau J
Ref : Naunyn Schmiedebergs Arch Pharmacol , :1 , 2023
Abstract : Viral respiratory diseases (VRDs) cause lung inflammation and inflammatory cytokine production. We study whether dapsone is responsible for its observed preventive treatment effects of the sustained viral RNA interferon response. Around 2008 and 2012, Korea's Dementia Management Act stipulated drastic changes in the administration of dementia medication by medical staff. Participants were randomized and we compared leprosy patients with VRDs after prescribing dapsone as a standard treatment from 2005 to 2019. Significance was evaluated based on the dapsone-prescribed (+) subgroup and the dapsone-unprescribed (-) subgroup of the VRD diagnosed (+) and VRD undiagnosed (-) subgroup. We analyzed VRD ( +)/(- with dapsone (+)/(-) group and used a T-test, and designed the equation of acetylation with dapsone and acetylcholine (AA) equation. The 6394 VRD participants who received the dapsone intervention compared to the 3255 VRD participants in the control group demonstrated at T2 VRD (+) dapsone (-) (mean (M) = 224.80, SD = 97.50): T3 VRD (-) dapsone (+) (M = 110.87, SD = 103.80), proving that VRD is low when dapsone is taken and high when it is not taken. The t value is 3.10, and the p value is 0.004395 (significant at p < 0.05). After an increase in VRDs peaked in 2009, bronchitis, COPD, and pneumonia surged in 2013. The AA equation was strongly negatively correlated with the prevalence of bronchitis and chronic obstructive pulmonary disease (COPD): with bronchitis, r(15) = -0.823189, p = 0.005519, and with COPD, r(15) = -0.8161, p = 0.000207 (significant at p < 0.05). Dapsone treated both bronchitis and COPD. This study provides theoretical clinical data to limit acetylcholine excess during the VRD pandemic for bronchitis, COPD, and pneumonia.
ESTHER : Lee_2023_Naunyn.Schmiedebergs.Arch.Pharmacol__1
PubMedSearch : Lee_2023_Naunyn.Schmiedebergs.Arch.Pharmacol__1
PubMedID: 36773052

Title : Polyurethane biodegradation by Serratia sp. HY-72 isolated from the intestine of the Asian mantis Hierodula patellifera - Kim_2022_Front.Microbiol_13_1005415
Author(s) : Kim JH , Choi SH , Park MG , Park DH , Son KH , Park HY
Ref : Front Microbiol , 13 :1005415 , 2022
Abstract : Polyurethane (PU), currently replacing existing synthetic materials worldwide, is a synthetic polymer derived from polyols, isocyanates, and a chain extender added by condensation reactions. PU wastes which are difficult to recycle, are commonly discarded in landfills and flow into ecosystems, thereby causing serious environmental problems. In recent years, insect-associated microbes have become a promising, eco-friendly strategy as an alternative to plastic recycling. This study aimed to evaluate the potential of Serratia sp. HY-72 strain isolated from the intestine of the Asian mantis (Hierodula patellifera) for PU degradation. The 65 kDa family I.3 lipase which degrades PU was identified and characterized, with a specific activity of 2,883 U mg(-1). The bacterial filtrates and the recombinant lipase degraded Impranil (a colloidal polyester-PU dispersion, 100 g l(-1)) by 85.24 and 78.35% after 72 h incubation, respectively. Fourier transform infrared spectroscopy analysis revealed changes in Impranil functional groups, with decreased C=O functional group and aliphatic chain signals, and increased N-H bending with C-N stretching and C-O stretching. The current study also revealed that the HY-72 strain biodegraded the commercial PU foams (polyester- and polyether- PU) with 23.95 and 10.95% weight loss after 2 weeks, respectively with changes in surface morphology and structure such as cracks, roughness, and surface roughening. Altogether, this is one of the few studies reporting biodegradation of PU by the insect-associated microbe. These findings suggest that the insect-associated microbe could be a promising resource for biodegradation and recycling of plastic waste.
ESTHER : Kim_2022_Front.Microbiol_13_1005415
PubMedSearch : Kim_2022_Front.Microbiol_13_1005415
PubMedID: 36601396
Gene_locus related to this paper: serli-a0a109z2v1

Title : A Multinational, Multicenter, Randomized, Double-Blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease - Han_2022_J.Clin.Neurol_18_428
Author(s) : Han HJ , Park MY , Park KW , Park KH , Choi SH , Kim HJ , Yang DW , Ebenezer E , Yang YH , Kewalram GM , Han SH
Ref : J Clin Neurol , 18 :428 , 2022
Abstract : BACKGROUND AND PURPOSE: Oral administration of cholinesterase inhibitors is often associated with adverse gastrointestinal effects, and so developing an alternative administration route, such as transdermal, is urgently needed. The primary objective of this study was to determine the efficacy and safety of the IPI-301 donepezil transdermal patch compared with donepezil tablets (control) in mild-to-moderate probable Alzheimer's disease (AD). METHODS: This prospective, randomized, double-blind, double-dummy, two-arm parallel, multicenter trial included 399 patients, among whom 303 completed the trial. For randomization, the patients were stratified based on previous treatment and donepezil dose; patients in each stratum were randomized to the test and control groups at a 1:1 ratio. RESULTS: The difference between the control group and the IPI-301 group, quantified as the Hodges-Lehmann estimate of location shift, was 0.00 (95% confidence interval: -1.00 to 1.33), with an upper limit of less than 2.02. The change in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score differed significantly between the IPI-301 and control groups (p=0.02). However, the changes in the full-itemized ADCS-ADL scores at week 24 did not differ significantly between the two groups. There were no differences between the two groups regarding the scores for the Clinician Interview-Based Impression of Change (p=0.9097), Mini-Mental State Examination (p=0.7018), Neuropsychiatric Inventory (p=0.7656), or Clinical Dementia Rating (p=0.9990). Adverse events, vital signs, and laboratory test results were comparable between the two groups. CONCLUSIONS: IPI-301 was safe and efficacious in improving cognitive function in patients with mild-to-moderate AD.
ESTHER : Han_2022_J.Clin.Neurol_18_428
PubMedSearch : Han_2022_J.Clin.Neurol_18_428
PubMedID: 35796268

Title : Platelet-rich plasma loaded nerve guidance conduit as implantable biocompatible materials for recurrent laryngeal nerve regeneration - Kim_2022_NPJ.Regen.Med_7_49
Author(s) : Kim JW , Kim JM , Choi ME , Jeon EJ , Park JM , Kim YM , Choi SH , Eom T , Shim BS , Choi JS
Ref : NPJ Regen Med , 7 :49 , 2022
Abstract : Vocal cord paralysis caused by recurrent laryngeal nerve (RLN) injury during thyroidectomy results in hoarseness, aspiration, and dyspnea. We evaluated the usefulness of nerve guidance conduits (NGCs) constructed from an asymmetric polycaprolactone (PCL)/Pluronic F127 porous membrane and filled with platelet-rich plasma (PRP) for functional RLN regeneration. We evaluated the proliferation and migration of Schwann cells (SCs) after PRP treatment in vitro. For the in vivo study, rabbits were divided into a non-loaded NGC group and a PRP-loaded NGC group. The left RLNs were resected and interposed with the NGCs. Functional and histological examinations of the vocal cords were performed. SC proliferation and migration increased in a PRP dose-dependent manner, with the PRP increasing the levels of neurotrophic factors, myelin-associated glycoprotein, and ERK. In vivo, the PRP group showed significantly better vocal cord mobility and less vocalis muscle atrophy than the non-loaded NGC group. Histologically, the ingrowth of nerve endings occurred more rapidly in the PRP group, and acetylcholinesterase, neurofilament, and S-100 expression in neural endings were significantly higher in the PRP group. Furthermore, transmission electron microscopy showed that myelinated axons were more tightly packed in the PRP group. This study shows that PRP-loaded NGCs provide a favorable environment for neural regeneration and suggests that this technique has therapeutic potential for promoting RLN recovery.
ESTHER : Kim_2022_NPJ.Regen.Med_7_49
PubMedSearch : Kim_2022_NPJ.Regen.Med_7_49
PubMedID: 36104458

Title : Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia - Moon_2022_Endocrinol.Metab.(Seoul)_37_575
Author(s) : Moon JH , Kim K , Choi SH
Ref : Endocrinol Metab (Seoul) , 37 :575 , 2022
Abstract : High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.
ESTHER : Moon_2022_Endocrinol.Metab.(Seoul)_37_575
PubMedSearch : Moon_2022_Endocrinol.Metab.(Seoul)_37_575
PubMedID: 36065644

Title : Protective effect of Carthamus tinctorius L. seed on oxidative stress and cognitive impairment induced by chronic alcohol consumption in mice - Choi_2018_Food.Sci.Biotechnol_27_1475
Author(s) : Choi SH , Lee AY , Park CH , Shin YS , Cho EJ
Ref : Food Sci Biotechnol , 27 :1475 , 2018
Abstract : Chronic alcohol consumption induces damage to the brain that can cause various forms of dementia. An abundance of acetaldehyde is produced by excessive alcohol consumption and accumulates in the body to induce oxidative stress, apoptosis, and inflammation in neuronal cells, which results in learning and cognitive decline. In the present study, C57BL/N mice were orally administered alcohol (16%) and Carthamus tinctorius L. seed (CTS) (100 and 200 mg/kg/day). Behavioral experiments showed that memory and cognitive abilities were significantly higher in the CTS groups than the alcohol-treated control group in the T-maze test, novel object recognition test, and Morris water maze test. In addition, CTS inhibited alcohol-induced lipid peroxidation and nitric oxide production in the brain, kidney, and liver. Moreover, alcohol increased acetylcholinesterase activity in the brain, but this was significantly decreased by the administration of CTS. Therefore, CTS may play role in the prevention of alcohol-related dementia.
ESTHER : Choi_2018_Food.Sci.Biotechnol_27_1475
PubMedSearch : Choi_2018_Food.Sci.Biotechnol_27_1475
PubMedID: 30319858

Title : Neuroprotective Effects of MAGL (Monoacylglycerol Lipase) Inhibitors in Experimental Ischemic Stroke - Choi_2018_Stroke_49_718
Author(s) : Choi SH , Arai AL , Mou Y , Kang B , Yen CC , Hallenbeck J , Silva AC
Ref : Stroke , 49 :718 , 2018
Abstract : BACKGROUND AND PURPOSE: MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue inflammatory response. Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia. METHODS: SHR (spontaneously hypertensive rats) and normotensive WKY (Wistar Kyoto) rats were subject to an intracortical injection of the potent vasoconstrictor endothelin-1, permanent occlusion of a distal segment of the middle cerebral artery via craniectomy, or transient occlusion of the middle cerebral artery by the intraluminal suture method. JZL184 or MJN110 was administered 60 minutes after focal cerebral ischemia. Infarct volumes, hemispheric swelling, and functional outcomes were assessed between days 1 to 28 by magnetic resonance imaging, histology, and behavioral tests. RESULTS: Pharmacological inhibition of MAGL significantly attenuated infarct volume and hemispheric swelling. MAGL inhibition also ameliorated sensorimotor deficits, suppressed inflammatory response, and decreased the number of degenerating neurons. These beneficial effects of MAGL inhibition were not fully abrogated by selective antagonists of cannabinoid receptors, indicating that the anti-inflammatory effects are caused by inhibition of eicosanoid production rather than by activation of cannabinoid receptors. CONCLUSIONS: Our results suggest that MAGL may contribute to the pathophysiology of focal cerebral ischemia and is thus a promising therapeutic target for the treatment of ischemic stroke.
ESTHER : Choi_2018_Stroke_49_718
PubMedSearch : Choi_2018_Stroke_49_718
PubMedID: 29440474

Title : Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models - Kim_2017_Arch.Pharm.Res_40_268
Author(s) : Kim MK , Chae YN , Ahn GJ , Shin CY , Choi SH , Yang EK , Sohn YS , Son MH
Ref : Arch Pharm Res , 40 :268 , 2017
Abstract : Dipeptidyl peptidase 4 (DPP4) is an adipokine that interrupts insulin signaling. The resulting insulin resistance exacerbates hepatic steatosis. We previously reported that the novel DPP4 inhibitor evogliptin improves insulin resistance. This study aimed to verify the therapeutic potential of evogliptin for fatty liver. Evogliptin treatment was initiated simultaneously with a high-fat diet (HFD) feeding in normal mice and in a post-24 week HFD-fed rats. In a prevention study, insulin sensitivity was preserved in evogliptin-treated mice after a 16-week treatment. Overall plasma lipid levels stayed lower and hepatic lipid accumulation was drastically suppressed by evogliptin treatment. Evogliptin reduced hepatic expression of Srebf1, a key transcriptional factor for lipogenesis. Additionally, DPP4 inhibitor-treated mice showed less weight gain. In a treatment study, after evogliptin treatment for 14 weeks in pre-established HFD-fed obese rats, weight loss was marginal, while hepatic lipid accumulation and liver damage assessed by measuring plasma aminotransferase levels were completely resolved, suggesting weight loss-independent beneficial effects on fatty liver. Moreover, reduction in plasma non-esterified fatty acids supported the improvement of insulin resistance by evogliptin treatment. Conclusively, our findings suggest that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis.
ESTHER : Kim_2017_Arch.Pharm.Res_40_268
PubMedSearch : Kim_2017_Arch.Pharm.Res_40_268
PubMedID: 27885461

Title : Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial - Park_2017_PLoS.One_12_e0182123
Author(s) : Park KW , Kim EJ , Han HJ , Shim YS , Kwon JC , Ku BD , Park KH , Yi HA , Kim KK , Yang DW , Lee HW , Kang H , Kwon OD , Kim S , Lee JH , Chung EJ , Park SW , Park MY , Yoon B , Kim BC , Seo SW , Choi SH
Ref : PLoS ONE , 12 :e0182123 , 2017
Abstract : BACKGROUND AND OBJECTIVE: Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs.
METHODS: Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD Assessment Scale-Cognitive subscale (ADAS-Cog) from the baseline to the end of the study.
RESULTS: Of the 300 patients, there were 206 patients in group 1 and 94 patients in group 2. The intention-to-treat group comprised 198 patients (group 1, n = 136; group 2, n = 46) during the 24-week study period. Demographic factors did not differ between group 1 and group 2. There were no significant differences in change in ADAS-cog between group 1 (-0.62+/-5.70) and group 2 (-0.23+/-5.98) after the 24-week rivastigmine patch therapy (p = 0.378). The patients in group 1 had a 0.63-point improvement from baseline on the Frontal Assessment Battery, while group 2 had a 0.16-point decline compared to baseline at the end of the study (p = 0.037). The rates of adverse events (AEs) (42.6 vs. 40.3%) and discontinuation due to AEs (10.3% vs. 4.3%) did not differ between the groups.
CONCLUSIONS: Although the efficacy and tolerability of rivastigmine patch therapy were not associated with WMH severity in patients with AD, some improvement in frontal function was observed in those with minimal WMHs. TRIAL REGISTRATION: ClinicalTrials.gov NCT01380288.
ESTHER : Park_2017_PLoS.One_12_e0182123
PubMedSearch : Park_2017_PLoS.One_12_e0182123
PubMedID: 28786987

Title : Clinical Predictors for Mild Cognitive Impairment Progression in a Korean Cohort - Shim_2016_Dement.Neurocogn.Disord_15_68
Author(s) : Shim YS , Yang DW , Yoon B , Lee Y , Hong CH , Seo SW , Yoon SJ , Jeong JH , Park MH , Choi SH , Kim SY
Ref : Dement Neurocogn Disord , 15 :68 , 2016
Abstract : Background and Purpose: Patients with mild cognitive impairment (MCI) and their caregivers are concerned with the likelihood and time course of progression to dementia. This study was performed to identify the clinical predictors of the MCI progression in a Korean registry, and investigated the effects of medications without evidence, frequently prescribed in clinical practice. Methods: Using a Korean cohort that included older adults with MCI who completed at least one follow-up visit, clinical characteristics and total medical expenses including prescribed medications were compared between two groups: progressed to dementia or not. Cox proportional hazards regression analysis was conducted. Results: During the mean 1.42+/-0.72 years, 215 (27.63%) of 778 participants progressed to dementia. The best predictors were age [hazard ratio (HR), 1.036; 95% confidence interval (CI), 1.006-1.067; p=0.018], apolipoprotein epsilon4 allele (HR, 2.247; 95% CI, 1.512-3.337; p<0.001), Clinical Dementia Rating scale-sum of boxes scores (HR, 1.367; 95% CI, 1.143-1.636; p=0.001), Instrumental Activities of Daily Living scores (HR, 1.035; 95% CI, 1.003-1.067; p=0.029), and lower Mini-Mental State Examination scores (HR, 0.892; 95% CI, 0.839-0.949; p<0.001). Total medical expenses were not different. Conclusions: Our data are in accordance with previous reports about clinical predictors for the progression from MCI to dementia. Total medical expenses were not different between groups with and without progression.
ESTHER : Shim_2016_Dement.Neurocogn.Disord_15_68
PubMedSearch : Shim_2016_Dement.Neurocogn.Disord_15_68
PubMedID: 30906345

Title : A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes - Yang_2015_Endocr.J_62_449
Author(s) : Yang HK , Min KW , Park SW , Chung CH , Park KS , Choi SH , Song KH , Kim DM , Lee MK , Sung YA , Baik SH , Kim IJ , Cha BS , Park JH , Ahn YB , Lee IK , Yoo SJ , Kim J , Park Ie B , Park TS , Yoon KH
Ref : Endocrine Journal , 62 :449 , 2015
Abstract : The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The primary objective was to alter HbA1c levels from baseline at a 24-week endpoint. The overall baseline mean age and body mass index were 56.20 +/- 9.77 years and 25.01 +/- 2.97 kg/m(2), respectively, and the HbA1c level was of 7.14 +/- 0.69 %. Anagliptin at 100 mg and 200 mg produced significant reductions in HbA1c (-0.50 +/- 0.45 % and -0.51 +/- 0.55%, respectively), and the placebo treatment resulted in an increase in HbA1c by 0.23 +/- 0.62 %. Both doses of anagliptin produced significant decreases in fasting plasma glucose (-0.53 +/- 1.25 mmol/L and -0.72 +/- 1.25 mmol/L, respectively) and the proinsulin/insulin ratio (-0.04 +/- 0.15 and -0.07 +/- 0.18, respectively) compared with placebo. No meaningful body weight changes from baseline were observed in three groups. Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. The incidences of adverse or serious adverse events were similar among the three study groups. Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes.
ESTHER : Yang_2015_Endocr.J_62_449
PubMedSearch : Yang_2015_Endocr.J_62_449
PubMedID: 25819061

Title : Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension - Jin_2015_Diabetes.Obes.Metab_17_511
Author(s) : Jin SM , Park SW , Yoon KH , Min KW , Song KH , Park KS , Park JY , Park IB , Chung CH , Baik SH , Choi SH , Lee HW , Lee IK , Kim DM , Lee MK
Ref : Diabetes Obes Metab , 17 :511 , 2015
Abstract : We conducted a 24-week, multicentre, double-blind, randomized study with a 28-week extension to compare the efficacy and safety of anagliptin and sitagliptin as an add-on to metformin in patients with type 2 diabetes. Patients inadequately controlled on metformin were randomized to either anagliptin (100 mg twice daily, n = 92) or sitagliptin (100 mg once daily, n = 88). The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to week 24. The mean changes in HbA1c were -0.85 +/- 0.70% (p < 0.0001) for anagliptin and -0.83 +/- 0.61% (p < 0.0001) for sitagliptin, with a mean difference of -0.02% (95% confidence interval of difference, -0.22 to 0.18%). In both groups, the fasting proinsulin : insulin ratio significantly decreased from baseline, with improved insulin secretion. Safety profiles were similar in each group. In conclusion, the non-inferiority of the efficacy of anagliptin to sitagliptin as an add-on therapy was established with regard to efficacy and safety.
ESTHER : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedSearch : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedID: 25523633

Title : Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease - Han_2014_Eur.Neurol_73_23
Author(s) : Han HJ , Kwon JC , Kim JE , Kim SG , Park JM , Park KW , Park KC , Park KH , Moon SY , Seo SW , Choi SH , Cho SJ
Ref : Eur Neurol , 73 :23 , 2014
Abstract : Background: The K variant of butyrylcholinesterase (BCHE-K) exhibits a reduced acetylcholine-hydrolyzing capacity; so the clinical response to rivastigmine may differ in Alzheimer's disease (AD) patients with the BCHE-K gene. Objective: To investigate the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine transdermal patch therapy in AD patients based on the BCHE-K gene. Methods: A total of 146 probable AD patients consented to genetic testing for butyrylcholinesterase and underwent the final efficacy evaluations. Responders were defined as patients with an equal or better score on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at 16 weeks compared to their baseline score. Results: BCHE-K carriers showed a lower responder rate on the ADAS-cog than non-carriers (38.2 vs. 61.7%, p = 0.02), and this trend was evident in AD patients with apolipoprotein E epsilon 4 (35 vs. 60.7%, p = 0.001). The presence of the BCHE-K allele predicted a worse response on the ADAS-cog (odds ratio 0.35, 95% confidence interval 0.14-0.87), after adjusting for demographic and baseline cognitive and functional variables. Conclusion: The BCHE-K genotype may be related to a poor cognitive response to rivastigmine patch or memantine add-on therapy, especially in the presence of apolipoprotein E epsilon 4. (c) 2014 S. Karger AG, Basel.
ESTHER : Han_2014_Eur.Neurol_73_23
PubMedSearch : Han_2014_Eur.Neurol_73_23
PubMedID: 25376930

Title : Identification of a new subfamily of salt-tolerant esterases from a metagenomic library of tidal flat sediment - Jeon_2012_Appl.Microbiol.Biotechnol_93_623
Author(s) : Jeon JH , Lee HS , Kim JT , Kim SJ , Choi SH , Kang SG , Lee JH
Ref : Applied Microbiology & Biotechnology , 93 :623 , 2012
Abstract : To search for novel lipolytic enzymes, a metagenomic library was constructed from the tidal flat sediment of Ganghwa Island in South Korea. By functional screening using tributyrin agar plates, 3 clones were selected from among the 80,050 clones of the fosmid library. The sequence analysis revealed that those clones contained different open reading frames, which showed 50-57% amino acid identity with putative lipolytic enzymes in the database. Based on the phylogenetic analysis, they were identified to encode novel members, which form a distinct and new subfamily in the family IV of bacterial lipolytic enzymes. The consensus sequence, GT(S)SA(G)G, encompassing the active site serine of the enzymes was different from the GDSAG motif, conserved in the other subfamily. The genes were expressed in Escherichia coli and recombinant proteins were purified as active soluble forms. The enzymes showed the highest activity toward p-nitrophenyl valerate (C5) and exhibited optimum activities at mesophilic temperature ranges and slightly alkaline pH. In particular, the enzymes displayed salt tolerance with over 50% of the maximum activity remained in the presence of 3 M NaCl (or KCl). In this study, we demonstrated that the metagenomic approach using marine tidal flat sediment as a DNA source expanded the diversity of lipolytic enzyme-encoding genes.
ESTHER : Jeon_2012_Appl.Microbiol.Biotechnol_93_623
PubMedSearch : Jeon_2012_Appl.Microbiol.Biotechnol_93_623
PubMedID: 21720822
Gene_locus related to this paper: 9bact-E40 , 9bact-E25 , 9bact-d8v1j5 , 9bact-d8v1j4 , 9bact-d8v1j3

Title : DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes - Kim_2012_Life.Sci_90_21
Author(s) : Kim MK , Chae YN , Kim HD , Yang EK , Cho EJ , Choi SH , Cheong YH , Kim HS , Kim HJ , Jo YW , Son MH , Kim SH , Shin CY
Ref : Life Sciences , 90 :21 , 2012
Abstract : AIM: To characterize the pharmacodynamic profile of DA-1229, a novel dipeptidyl peptidase (DPP) 4 inhibitor. MAIN
METHODS: Enzyme inhibition assays against DPP4, DPP8 and DPP9. Antidiabetic effects of DA-1229 in HF-DIO mice and young db/db mice. KEY FINDINGS: DA-1229 was shown to potently inhibit the DPP4 enzyme in human and murine soluble forms and the human membrane-bound form with IC(50) values of 0.98, 3.59 and 1.26 nM, respectively. As a reversible and competitive inhibitor, DA-1229 was more selective to human DPP4 (6000-fold) than to human DPP8 and DPP9. DA-1229 (0.1-3mg/kg) dose-dependently inhibited plasma DPP4 activity, leading to increased levels of plasma GLP-1 and insulin, and thereby lowering blood glucose levels in mice. In high fat diet-fed (HF) mice, a single oral dose of 100mg/kg of DA-1229 reduced plasma DPP4 activity by over 80% during a 24h period. Long-term treatment with DA-1229 for 8 weeks revealed significant improvements in glucose intolerance and insulin resistance, accompanied by significant body weight reduction. However, it remains unclear whether there is a direct causal relationship between DPP4 inhibition and body weight reduction. In young db/db mice, the DA-1229 treatment significantly reduced blood glucose excursions for the first 2 weeks, resulting in significantly lower levels of HbA1c at the end of the study. Furthermore, the pancreatic insulin content of the treatment group was significantly higher than that of the db/db control. SIGNIFICANCE: DA-1229 as a novel and selective DPP4 inhibitor improves the insulin sensitivity in HF mice and delays the onset of diabetes in young db/db mice.
ESTHER : Kim_2012_Life.Sci_90_21
PubMedSearch : Kim_2012_Life.Sci_90_21
PubMedID: 22056373

Title : Draft genome sequence of Fusobacterium nucleatum subsp. fusiforme ATCC 51190T - Park_2012_J.Bacteriol_194_5445
Author(s) : Park SN , Kong SW , Park MS , Lee JW , Cho E , Lim YK , Choi MH , Kim HS , Chang YH , Shin JH , Park HS , Choi SH , Kook JK
Ref : Journal of Bacteriology , 194 :5445 , 2012
Abstract : Fusobacterium nucleatum, one of the major causative bacteria of periodontitis, is classified into five subspecies (nucleatum, polymorphum, vincentii, animalis, and fusiforme) on the basis of the several phenotypic characteristics and DNA homology. This is the first report of the draft genome sequence of F. nucleatum subsp. fusiforme ATCC 51190(T).
ESTHER : Park_2012_J.Bacteriol_194_5445
PubMedSearch : Park_2012_J.Bacteriol_194_5445
PubMedID: 22965077
Gene_locus related to this paper: fusnu-j1awj6 , fusnv-c7xmx1

Title : Draft genome sequence of Fusobacterium nucleatum ChDC F128, isolated from a periodontitis lesion - Park_2012_J.Bacteriol_194_6322
Author(s) : Park SN , Kong SW , Kim HS , Park MS , Lee JW , Cho E , Lim YK , Choi MH , Chang YH , Shin JH , Park HS , Choi SH , Kook JK
Ref : Journal of Bacteriology , 194 :6322 , 2012
Abstract : Fusobacterium nucleatum is classified into five subspecies. F. nucleatum ChDC F128 was isolated from a periodontitis lesion and proposed as a new subspecies based on the comparison of the nucleotide sequences of the RNA polymerase beta subunit and zinc protease genes. Here, we report the draft genome sequence of the strain.
ESTHER : Park_2012_J.Bacteriol_194_6322
PubMedSearch : Park_2012_J.Bacteriol_194_6322
PubMedID: 23105064
Gene_locus related to this paper: fusnu-j8vid6

Title : Strain-dependent diversity in the Pseudomonas aeruginosa quorum-sensing regulon - Chugani_2012_Proc.Natl.Acad.Sci.U.S.A_109_E2823
Author(s) : Chugani S , Kim BS , Phattarasukol S , Brittnacher MJ , Choi SH , Harwood CS , Greenberg EP
Ref : Proc Natl Acad Sci U S A , 109 :E2823 , 2012
Abstract : Quorum sensing allows bacteria to sense and respond to changes in population density. Acyl-homoserine lactones serve as quorum-sensing signals for many Proteobacteria, and acyl-homoserine lactone signaling is known to control cooperative activities. Quorum-controlled activities vary from one species to another. Quorum-sensing controls a constellation of genes in the opportunistic pathogen Pseudomonas aeruginosa, which thrives in a number of habitats ranging from soil and water to animal hosts. We hypothesized that there would be significant variation in quorum-sensing regulons among strains of P. aeruginosa isolated from different habitats and that differences in the quorum-sensing regulons might reveal insights about the ecology of P. aeruginosa. As a test of our hypothesis we used RNA-seq to identify quorum-controlled genes in seven P. aeruginosa isolates of diverse origins. Although our approach certainly overlooks some quorum-sensing-regulated genes we found a shared set of genes, i.e., a core quorum-controlled gene set, and we identified distinct, strain-variable sets of quorum-controlled genes, i.e., accessory genes. Some quorum-controlled genes in some strains were not present in the genomes of other strains. We detected a correlation between traits encoded by some genes in the strain-variable subsets of the quorum regulons and the ecology of the isolates. These findings indicate a role for quorum sensing in extension of the range of habitats in which a species can thrive. This study also provides a framework for understanding the molecular mechanisms by which quorum-sensing systems operate, the evolutionary pressures by which they are maintained, and their importance in disparate ecological contexts.
ESTHER : Chugani_2012_Proc.Natl.Acad.Sci.U.S.A_109_E2823
PubMedSearch : Chugani_2012_Proc.Natl.Acad.Sci.U.S.A_109_E2823
PubMedID: 22988113
Gene_locus related to this paper: pseae-PA1558 , pseae-PA2927 , pseae-PA2949 , pseae-PA3695 , pseae-PA5080 , pseae-q9i252

Title : Novel lipolytic enzymes identified from metagenomic library of deep-sea sediment - Jeon_2011_Evid.Based.Complement.Alternat.Med_2011_271419
Author(s) : Jeon JH , Kim JT , Lee HS , Kim SJ , Kang SG , Choi SH , Lee JH
Ref : Evid Based Complement Alternat Med , 2011 :271419 , 2011
Abstract : Metagenomic library was constructed from a deep-sea sediment sample and screened for lipolytic activity. Open-reading frames of six positive clones showed only 33-58% amino acid identities to the known proteins. One of them was assigned to a new group while others were grouped into Families I and V or EstD Family. By employing a combination of approaches such as removing the signal sequence, coexpression of chaperone genes, and low temperature induction, we obtained five soluble recombinant proteins in Escherichia coli. The purified enzymes had optimum temperatures of 30-35 degrees C and the cold-activity property. Among them, one enzyme showed lipase activity by preferentially hydrolyzing p-nitrophenyl palmitate and p-nitrophenyl stearate and high salt resistance with up to 4 M NaCl. Our research demonstrates the feasibility of developing novel lipolytic enzymes from marine environments by the combination of functional metagenomic approach and protein expression technology.
ESTHER : Jeon_2011_Evid.Based.Complement.Alternat.Med_2011_271419
PubMedSearch : Jeon_2011_Evid.Based.Complement.Alternat.Med_2011_271419
PubMedID: 21845199
Gene_locus related to this paper: 9bact-d8v1j0 , 9bact-d8v1i9 , 9bact-d8v1i5 , 9bact-d8v1i8 , 9bact-d8v1i6 , 9bact-d8v1i7

Title : Complete genome sequence of Vibrio vulnificus MO6-24\/O - Park_2011_J.Bacteriol_193_2062
Author(s) : Park JH , Cho YJ , Chun J , Seok YJ , Lee JK , Kim KS , Lee KH , Park SJ , Choi SH
Ref : Journal of Bacteriology , 193 :2062 , 2011
Abstract : Vibrio vulnificus is the causative agent of life-threatening septicemia and severe wound infections. Here, we announce the complete annotated genome sequence of V. vulnificus MO6-24/O, isolated from a patient with septicemia. When it is compared with previously known V. vulnificus genomes, the genome of this bacterium shows a unique genetic makeup, including phagelike elements, carbohydrate metabolism-related genes, and the superintegron.
ESTHER : Park_2011_J.Bacteriol_193_2062
PubMedSearch : Park_2011_J.Bacteriol_193_2062
PubMedID: 21317338
Gene_locus related to this paper: vibvu-VV10305 , vibvu-VV11137 , vibvu-VV11321 , vibvu-VV20739 , vibvu-VV20967 , vibvu-VV21548 , vibvy-y856

Title : Major chimpanzee-specific structural changes in sperm development-associated genes - Kim_2011_Funct.Integr.Genomics_11_507
Author(s) : Kim RN , Kim DW , Choi SH , Chae SH , Nam SH , Kim A , Kang A , Park KH , Lee YS , Hirai M , Suzuki Y , Sugano S , Hashimoto K , Kim DS , Park HS
Ref : Funct Integr Genomics , 11 :507 , 2011
Abstract : A comprehensive analysis of transcriptional structures of chimpanzee sperm development-associated genes is of significant interest for deeply understanding sperm development and male reproductive process. In this study, we sequenced 7,680 clones from a chimpanzee testis full-length cDNA library and obtained 1,933 nonredundant high-quality full-length cDNA sequences. Comparative analysis between human and chimpanzee showed that 78 sperm development-associated genes, most of which were yet uncharacterized, had undergone severe structural changes (mutations at the start/stop codons, INDELs, alternative splicing variations and fusion forms) on genomic and transcript levels throughout chimpanzee evolution. Specifically, among the 78 sperm development-associated genes, 39 including ODF2, UBC, and CD59 showed markedly chimpanzee-specific structural changes. Through dN/dS analysis, we found that 56 transcripts (including seven sperm development-associated genes) had values of greater than one when comparing human and chimpanzee DNA sequences, whereas the values were less than one when comparing humans and orangutans. Gene ontology annotation and expression profiling showed that the chimpanzee testis transcriptome was enriched with genes that are associated with chimpanzee male germ cell development. Taken together, our study provides the first comprehensive molecular evidence that many chimpanzee sperm development-associated genes had experienced severe structural changes over the course of evolution on genomic and transcript levels.
ESTHER : Kim_2011_Funct.Integr.Genomics_11_507
PubMedSearch : Kim_2011_Funct.Integr.Genomics_11_507
PubMedID: 21484476
Gene_locus related to this paper: pantr-BCHE , pantr-k7c7k7 , pantr-g2hih9 , pantr-g2hj61

Title : A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis - Cho_2011_Diabetes.Res.Clin.Pract_91_72
Author(s) : Cho JM , Jang HW , Cheon H , Jeong YT , Kim DH , Lim YM , Choi SH , Yang EK , Shin CY , Son MH , Kim SH , Kim HJ , Lee MS
Ref : Diabetes Res Clin Pract , 91 :72 , 2011
Abstract : We studied the effect of a novel dipeptidyl peptidase IV (DPP IV) inhibitor, DA-1229, on blood glucose profile and pancreatic beta-cell mass in established diabetes after streptozotocin (STZ) treatment. Mice that developed diabetes after administration of STZ 100mg/kg were treated with DA-1229 for 13 weeks. DA-1229 significantly reduced plasma DPP IV activity, and enhanced glucagon-like peptide 1 (GLP-1) levels. In STZ-treated mice fed DA-1229 (STZ-DA), blood glucose levels were significantly lower than those in diabetic mice fed normal chow (STZ-NC). Basal and glucose-stimulated insulin secretion and glucose tolerance assessed by intraperitoneal glucose tolerance test were significantly improved by DA-1229 administration. Volume density of beta-cell was significantly increased in STZ-DA mice compared to STZ-NC mice, suggesting that DA-1229-mediated amelioration of established diabetes was due to beneficial effect of DA-1229 on beta-cell mass. The number of replicating beta-cells and that of scattered small beta-cell unit representing beta-cell neogenesis were significantly increased in STZ-DA mice compared to STZ-NC mice, explaining increased beta-cell mass by DA-1229. The expression of PDX-1, a downstream mediator of GLP-1 action, was increased in islets of STZ-DA mice compared to STZ-NC mice. These results suggest a therapeutic potential of DA-1229 in diabetes, particularly that associated with decreased beta-cell mass.
ESTHER : Cho_2011_Diabetes.Res.Clin.Pract_91_72
PubMedSearch : Cho_2011_Diabetes.Res.Clin.Pract_91_72
PubMedID: 21093089

Title : Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes - Kim_2011_Bioorg.Med.Chem.Lett_21_3809
Author(s) : Kim HJ , Kwak WY , Min JP , Lee JY , Yoon TH , Kim HD , Shin CY , Kim MK , Choi SH , Kim HS , Yang EK , Cheong YH , Chae YN , Park KJ , Jang JM , Choi SJ , Son MH , Kim SH , Yoo M , Lee BJ
Ref : Bioorganic & Medicinal Chemistry Lett , 21 :3809 , 2011
Abstract : A series of beta-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(t-butoxymethyl)-piperaz in-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.
ESTHER : Kim_2011_Bioorg.Med.Chem.Lett_21_3809
PubMedSearch : Kim_2011_Bioorg.Med.Chem.Lett_21_3809
PubMedID: 21570283

Title : Draft genome sequence of Shewanella sp. strain HN-41, which produces arsenic-sulfide nanotubes - Kim_2011_J.Bacteriol_193_5039
Author(s) : Kim DH , Jiang S , Lee JH , Cho YJ , Chun J , Choi SH , Park HS , Hur HG
Ref : Journal of Bacteriology , 193 :5039 , 2011
Abstract : The dissimilatory metal reducing bacterium Shewanella sp. strain HN-41 was first reported to produce novel photoactive As-S nanotubes via reduction of As(V) and S(2)O(3)(2-) under anaerobic conditions. Here we report the draft genome sequence and annotation of strain HN-41.
ESTHER : Kim_2011_J.Bacteriol_193_5039
PubMedSearch : Kim_2011_J.Bacteriol_193_5039
PubMedID: 21868804
Gene_locus related to this paper: 9gamm-f7ru18 , 9gamm-f7rlm5 , 9gamm-f7ris6 , 9gamm-f7rp63

Title : Novel metagenome-derived carboxylesterase that hydrolyzes beta-lactam antibiotics - Jeon_2011_Appl.Environ.Microbiol_77_7830
Author(s) : Jeon JH , Kim SJ , Lee HS , Cha SS , Lee JH , Yoon SH , Koo BS , Lee CM , Choi SH , Lee SH , Kang SG
Ref : Applied Environmental Microbiology , 77 :7830 , 2011
Abstract : It has been proposed that family VIII carboxylesterases and class C beta-lactamases are phylogenetically related; however, none of carboxylesterases has been reported to hydrolyze beta-lactam antibiotics except nitrocefin, a nonclinical chromogenic substrate. Here, we describe the first example of a novel carboxylesterase derived from a metagenome that is able to cleave the amide bond of various beta-lactam substrates and the ester bond of p-nitrophenyl esters. A clone with lipolytic activity was selected by functional screening of a metagenomic library using tributyrin agar plates. The sequence analysis of the clone revealed the presence of an open reading frame (estU1) encoding a polypeptide of 426 amino acids, retaining an S-X-X-K motif that is conserved in class C beta-lactamases and family VIII carboxylesterases. The gene was overexpressed in Escherichia coli, and the purified recombinant protein (EstU1) was further characterized. EstU1 showed esterase activity toward various chromogenic p-nitrophenyl esters. In addition, it exhibited hydrolytic activity toward nitrocefin, leading us to investigate whether EstU1 could hydrolyze beta-lactam antibiotics. EstU1 was able to hydrolyze first-generation beta-lactam antibiotics, such as cephalosporins, cephaloridine, cephalothin, and cefazolin. In a kinetic study, EstU1 showed a similar range of substrate affinities for both p-nitrophenyl butyrate and first-generation cephalosporins while the turnover efficiency for the latter was much lower. Furthermore, site-directed mutagenesis studies revealed that the catalytic triad of EstU1 plays a crucial role in hydrolyzing both ester bonds of p-nitrophenyl esters and amide bonds of the beta-lactam ring of antibiotics, implicating the predicted catalytic triad of EstU1 in both activities.
ESTHER : Jeon_2011_Appl.Environ.Microbiol_77_7830
PubMedSearch : Jeon_2011_Appl.Environ.Microbiol_77_7830
PubMedID: 21908637

Title : Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease - Han_2011_J.Clin.Neurol_7_137
Author(s) : Han HJ , Lee JJ , Park SA , Park HY , Kim JE , Shim YS , Shim DS , Kim EJ , Yoon SJ , Choi SH
Ref : J Clin Neurol , 7 :137 , 2011
Abstract : BACKGROUND AND PURPOSE: The goal of this study was to estimate the efficacy and safety of the rivastigmine transdermal patch in patients with probable Alzheimer's disease (AD) who cannot tolerate or do not respond to oral cholinesterase inhibitors (ChEIs). METHODS: A 24-week, prospective, open-label, single-arm, multicenter study was conducted from June 2009 to June 2010 in patients with probable AD. The enrolled patients had either a poor response or a decline in global function after treatment with oral ChEIs, or they were not able to tolerate treatment with oral ChEIs due to adverse events such as nausea or vomiting. A poor response was defined as a decrease of at least 2 points on the Korean version of the Mini-Mental State Examination (K-MMSE) within the previous 6 months (the decline in global function was determined by the investigator or caregiver). The efficacy of treatment was assessed using a follow-up Clinical Global Impression of Change (CGIC) assessment and K-MMSE conducted after 24 weeks, and safety was measured by the occurrence of adverse events and patient disposition. RESULTS: In total, 164 patients aged 74.7+/-7.52 years (mean+/-SD) and with 5.12+/-3.64 years of education were included. The study was completed by 70% of the patients (n=116), with 12.2% discontinuing due to adverse events. The most frequently reported adverse events (11%) were skin lesions, such as erythema or itching, followed by gastrointestinal problems (1.2%). Either an improvement or no decline in CGIC scores was reported for 82% of the patients. CONCLUSIONS: The immediate switching of patients from an oral ChEI to the rivastigmine transdermal patch without a washout period was safe and well tolerated by the probable-AD patients in this study.
ESTHER : Han_2011_J.Clin.Neurol_7_137
PubMedSearch : Han_2011_J.Clin.Neurol_7_137
PubMedID: 22087207

Title : Complete genome sequence of Halalkalicoccus jeotgali B3(T), an extremely halophilic archaeon - Roh_2010_J.Bacteriol_192_4528
Author(s) : Roh SW , Nam YD , Nam SH , Choi SH , Park HS , Bae JW
Ref : Journal of Bacteriology , 192 :4528 , 2010
Abstract : Halalkalicoccus jeotgali B3(T), isolated from salt-fermented seafood from South Korea, is an extremely halophilic archaeon belonging to the family Halobacteriaceae. Here, we present the complete genome sequence of the type strain H. jeotgali B3(T) (3,698,650 bp, with a G+C content of 62.5%), which consists of one chromosome and six plasmids. This is the first complete genome sequence of the Halalkalicoccus species.
ESTHER : Roh_2010_J.Bacteriol_192_4528
PubMedSearch : Roh_2010_J.Bacteriol_192_4528
PubMedID: 20601480
Gene_locus related to this paper: haljb-d8j7v7

Title : Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex - Cai_2010_J.Biol.Chem_285_4268
Author(s) : Cai Y , Jin J , Swanson SK , Cole MD , Choi SH , Florens L , Washburn MP , Conaway JW , Conaway RC
Ref : Journal of Biological Chemistry , 285 :4268 , 2010
Abstract : Human MOF (MYST1), a member of the MYST (Moz-Ybf2/Sas3-Sas2-Tip60) family of histone acetyltransferases (HATs), is the human ortholog of the Drosophila males absent on the first (MOF) protein. MOF is the catalytic subunit of the male-specific lethal (MSL) HAT complex, which plays a key role in dosage compensation in the fly and is responsible for a large fraction of histone H4 lysine 16 (H4K16) acetylation in vivo. MOF was recently reported to be a component of a second HAT complex, designated the non-specific lethal (NSL) complex (Mendjan, S., Taipale, M., Kind, J., Holz, H., Gebhardt, P., Schelder, M., Vermeulen, M., Buscaino, A., Duncan, K., Mueller, J., Wilm, M., Stunnenberg, H. G., Saumweber, H., and Akhtar, A. (2006) Mol. Cell 21, 811-823). Here we report an analysis of the subunit composition and substrate specificity of the NSL complex. Proteomic analyses of complexes purified through multiple candidate subunits reveal that NSL is composed of nine subunits. Two of its subunits, WD repeat domain 5 (WDR5) and host cell factor 1 (HCF1), are shared with members of the MLL/SET family of histone H3 lysine 4 (H3K4) methyltransferase complexes, and a third subunit, MCRS1, is shared with the human INO80 chromatin-remodeling complex. In addition, we show that assembly of the MOF HAT into MSL or NSL complexes controls its substrate specificity. Although MSL-associated MOF acetylates nucleosomal histone H4 almost exclusively on lysine 16, NSL-associated MOF exhibits a relaxed specificity and also acetylates nucleosomal histone H4 on lysines 5 and 8.
ESTHER : Cai_2010_J.Biol.Chem_285_4268
PubMedSearch : Cai_2010_J.Biol.Chem_285_4268
PubMedID: 20018852
Gene_locus related to this paper: human-KANSL3

Title : Genome sequences of Escherichia coli B strains REL606 and BL21(DE3) - Jeong_2009_J.Mol.Biol_394_644
Author(s) : Jeong H , Barbe V , Lee CH , Vallenet D , Yu DS , Choi SH , Couloux A , Lee SW , Yoon SH , Cattolico L , Hur CG , Park HS , Segurens B , Kim SC , Oh TK , Lenski RE , Studier FW , Daegelen P , Kim JF
Ref : Journal of Molecular Biology , 394 :644 , 2009
Abstract : Escherichia coli K-12 and B have been the subjects of classical experiments from which much of our understanding of molecular genetics has emerged. We present here complete genome sequences of two E. coli B strains, REL606, used in a long-term evolution experiment, and BL21(DE3), widely used to express recombinant proteins. The two genomes differ in length by 72,304 bp and have 426 single base pair differences, a seemingly large difference for laboratory strains having a common ancestor within the last 67 years. Transpositions by IS1 and IS150 have occurred in both lineages. Integration of the DE3 prophage in BL21(DE3) apparently displaced a defective prophage in the lambda attachment site of B. As might have been anticipated from the many genetic and biochemical experiments comparing B and K-12 over the years, the B genomes are similar in size and organization to the genome of E. coli K-12 MG1655 and have >99% sequence identity over approximately 92% of their genomes. E. coli B and K-12 differ considerably in distribution of IS elements and in location and composition of larger mobile elements. An unexpected difference is the absence of a large cluster of flagella genes in B, due to a 41 kbp IS1-mediated deletion. Gene clusters that specify the LPS core, O antigen, and restriction enzymes differ substantially, presumably because of horizontal transfer. Comparative analysis of 32 independently isolated E. coli and Shigella genomes, both commensals and pathogenic strains, identifies a minimal set of genes in common plus many strain-specific genes that constitute a large E. coli pan-genome.
ESTHER : Jeong_2009_J.Mol.Biol_394_644
PubMedSearch : Jeong_2009_J.Mol.Biol_394_644
PubMedID: 19786035
Gene_locus related to this paper: eco57-b3a913 , ecoli-Aes , ecoli-rutD , ecoli-bioh , ecoli-dlhh , ecoli-entf , ecoli-fes , ecoli-mhpc , ecoli-pldb , ecoli-ptrb , ecoli-yafa , ecoli-yaim , ecoli-ybff , ecoli-ycfp , ecoli-ycjy , ecoli-yeiG , ecoli-YFBB , ecoli-yghX , ecoli-yhet , ecoli-yiel , ecoli-yjfp , ecoli-YNBC , ecoli-ypfh , ecoli-yqia , ecoli-YfhR

Title : Comparative homology modeling-inspired protein engineering for improvement of catalytic activity of Mugil cephalus epoxide hydrolase - Choi_2009_Biotechnol.Lett_31_1617
Author(s) : Choi SH , Kim HS , Lee EY
Ref : Biotechnol Lett , 31 :1617 , 2009
Abstract : The epoxide hydrolase (EH) of a marine fish, Mugil cephalus, was engineered to improve the catalytic activity based on comparative homology modeling. The 3-D crystal structure of the EH from Aspergillus niger was used as a template. A triple point mutant, F193Y for spatial orientation of the nucleophile (D199), W200L for removing electron density overlap between W200 and Y348, and E378D for good charge relay in the active site, was developed. The initial hydrolysis rate, the reaction time to reach 98 %ee, and yield were enhanced up to 35-fold, 26-fold and 32%, respectively, by homology modeling-inspired site-directed mutagenesis of M. cephalus EH.
ESTHER : Choi_2009_Biotechnol.Lett_31_1617
PubMedSearch : Choi_2009_Biotechnol.Lett_31_1617
PubMedID: 19547925

Title : Genome sequence of the probiotic bacterium Bifidobacterium animalis subsp. lactis AD011 - Kim_2009_J.Bacteriol_191_678
Author(s) : Kim JF , Jeong H , Yu DS , Choi SH , Hur CG , Park MS , Yoon SH , Kim DW , Ji GE , Park HS , Oh TK
Ref : Journal of Bacteriology , 191 :678 , 2009
Abstract : Bifidobacterium animalis subsp. lactis is a probiotic bacterium that naturally inhabits the guts of most mammals, including humans. Here we report the complete genome sequence of B. animalis subsp. lactis AD011 that was isolated from an infant fecal sample. Biological functions encoded in a single circular chromosome of 1,933,695 bp, smallest among the completely sequenced bifidobacterial genomes, are suggestive of their probiotic functions, such as utilization of bifidogenic factors and a variety of glycosidic enzymes and biosynthesis of polysaccharides.
ESTHER : Kim_2009_J.Bacteriol_191_678
PubMedSearch : Kim_2009_J.Bacteriol_191_678
PubMedID: 19011029
Gene_locus related to this paper: bifan-b2ea73 , bifan-b2eam2 , bifan-b2eck9 , bifas-c6ahs7 , biflb-c6a5u1 , bifa0-b8dw94 , bifan-b2e8c8

Title : 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1 - Byun_2008_Cancer.Lett_266_238
Author(s) : Byun HM , Choi SH , Laird PW , Trinh B , Siddiqui MA , Marquez VE , Yang AS
Ref : Cancer Letters , 266 :238 , 2008
Abstract : 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine (NPEOC-DAC), decitabine with a modification of the N4 position of the azacitidine ring can be used to inhibit DNA methyltransferase. This modification protects the azacitidine ring and can be cleaved by carboxylesterase to release decitabine. NPEOC-DAC was 23-fold less potent at low doses (<10microM) than decitabine at inhibiting DNA methylation, and was also associated with a 3-day delay in its effect. However, at doses > or = 10microM NPEOC-DAC was more effective at inhibiting DNA methylation. Theses differences between decitabine and NPEOC-DAC are dependent on the cleavage of the carboxylester bond, and could be potentially exploited pharmacologically.
ESTHER : Byun_2008_Cancer.Lett_266_238
PubMedSearch : Byun_2008_Cancer.Lett_266_238
PubMedID: 18499340

Title : Beta-secretase (BACE1) inhibitors from Perilla frutescens var. acuta - Choi_2008_Arch.Pharm.Res_31_183
Author(s) : Choi SH , Hur JM , Yang EJ , Jun M , Park HJ , Lee KB , Moon E , Song KS
Ref : Arch Pharm Res , 31 :183 , 2008
Abstract : In the course of screening for anti-dementia agents from natural products, two beta-secretase (BACE1) inhibitors were isolated from the methanolic extract of Perilla frutescens var. acuta and identified as luteolin (1) and rosmarinic acid (2) with IC50 values of 5.0 x 10(-7) M and 2.1 x 10(-5) M, respectively. They inhibited BACE1 in a non-competitive manner with a substrate in Dixon plots, suggesting that they might bind to either beta-secretase subsite or to another regulatory site. Kivalues of 1 and 2 were 6.2 x 10(-5) M and 3.9 x 10(-5) M, respectively. They were less inhibitory against other enzymes such as alpha-secretase (TACE), acetylcholine esterase (AchE), chymotrypsin, and elastase, indicating that they were relatively specific inhibitors of BACE1.
ESTHER : Choi_2008_Arch.Pharm.Res_31_183
PubMedSearch : Choi_2008_Arch.Pharm.Res_31_183
PubMedID: 18365688

Title : Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease - Choi_2008_Dement.Geriatr.Cogn.Disord_25_445
Author(s) : Choi SH , Kim SY , Na HR , Kim BK , Yang DW , Kwon JC , Park MY
Ref : Dementia & Geriatric Cognitive Disorders , 25 :445 , 2008
Abstract : BACKGROUND/AIMS: The possible influence of apolipoprotein E (ApoE) genotype on the response to acetylcholinesterase inhibitor therapy in patients with Alzheimer's disease (AD) remains a matter of controversy. In order to address this issue, we investigated the effects of ApoE genotype on the clinical response to donepezil in patients with mild to moderate AD.
METHODS: An open study was carried out in 51 patients with probable AD who were treated with 5-10 mg of donepezil per day for 48 weeks.
RESULTS: Eighteen (35.3%) of the 51 patients had 1 or 2 ApoE epsilon4 alleles. ApoE epsilon4 carriers with AD showed a mean 1.1-point increase from the baseline score of 23.9 on the 70-point Alzheimer's Disease Assessment Scale-Cognitive Component at 48 weeks, while the ApoE epsilon4 noncarrier group showed a 3.1-point increase from the baseline score of 22.5 (p = 0.03). The ApoE epsilon4 carrier group exhibited a mean 0.13-point worsening from the baseline score of 0.97 on the Korean Instrumental Activities of Daily Living at 48 weeks, while the ApoE epsilon4 noncarrier group exhibited a 0.17-point worsening from the baseline score of 0.64 (p = 0.05). CONCLUSION: AD patients who carry the ApoE epsilon4 allele may respond more favorably to donepezil than epsilon4 noncarriers.
ESTHER : Choi_2008_Dement.Geriatr.Cogn.Disord_25_445
PubMedSearch : Choi_2008_Dement.Geriatr.Cogn.Disord_25_445
PubMedID: 18401173

Title : Complete genome sequence of Leuconostoc citreum KM20 - Kim_2008_J.Bacteriol_190_3093
Author(s) : Kim JF , Jeong H , Lee JS , Choi SH , Ha M , Hur CG , Kim JS , Lee S , Park HS , Park YH , Oh TK
Ref : Journal of Bacteriology , 190 :3093 , 2008
Abstract : Leuconostoc citreum is one of the most prevalent lactic acid bacteria during the manufacturing process of kimchi, the best-known Korean traditional dish. We have determined the complete genome sequence of L. citreum KM20. It consists of a 1.80-Mb chromosome and four circular plasmids and reveals genes likely involved in kimchi fermentation and its probiotic effects.
ESTHER : Kim_2008_J.Bacteriol_190_3093
PubMedSearch : Kim_2008_J.Bacteriol_190_3093
PubMedID: 18281406
Gene_locus related to this paper: leuck-b1mwg5 , leuck-b1mwm3 , leuck-b1mxa8 , leuck-b1mxk9 , leuck-b1my46 , leuck-b1mz26 , leuck-b1mwr2

Title : Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats - Lee_2008_J.Gene.Med_10_260
Author(s) : Lee Y , Kwon MK , Kang ES , Park YM , Choi SH , Ahn CW , Kim KS , Park CW , Cha BS , Kim SW , Sung JK , Lee EJ , Lee HC
Ref : J Gene Med , 10 :260 , 2008
Abstract : BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that plays an important role in glucose homeostasis. Its functions include glucose-stimulated insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in appetite and food intake. Despite the numerous antidiabetic properties of GLP-1, its therapeutic potential is limited by its short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV. The present study aimed to demonstrate the therapeutic effects of constitutively expressed GLP-1 in an overt type 2 diabetic animal model using an adenoviral vector system.
METHODS: A novel plasmid (pAAV-ILGLP-1) and recombinant adenoviral vector (Ad-ILGLP-1) were constructed with the cytomegalovirus promoter and insulin leader sequence followed by GLP-1(7-37) cDNA.
RESULTS: The results of an enzyme-linked immunosorbent assay showed significantly elevated levels of GLP-1(7-37) secreted by human embryonic kidney cells transfected with the construct containing the leader sequence. A single intravenous administration of Ad-ILGLP-1 into 12-week-old Zucker diabetic fatty (ZDF) rats, which have overt type 2 diabetes mellitus (T2DM), achieved near normoglycemia for 3 weeks and improved utilization of blood glucose in glucose tolerance tests. Circulating plasma levels of GLP-1 increased in GLP-1-treated ZDF rats, but diminished 21 days after treatment. When compared with controls, Ad-ILGLP-1-treated ZDF rats had a lower homeostasis model assessment for insulin resistance score indicating amelioration in insulin resistance. Immunohistochemical staining showed that cells expressing GLP-1 were found in the livers of GLP-1-treated ZDF rats.
CONCLUSIONS: These data suggest that GLP-1 gene therapy can improve glucose homeostasis in fully developed diabetic animal models and may be a promising treatment modality for T2DM in humans.
ESTHER : Lee_2008_J.Gene.Med_10_260
PubMedSearch : Lee_2008_J.Gene.Med_10_260
PubMedID: 18085721

Title : Genomic blueprint of Hahella chejuensis, a marine microbe producing an algicidal agent - Jeong_2005_Nucleic.Acids.Res_33_7066
Author(s) : Jeong H , Yim JH , Lee C , Choi SH , Park YK , Yoon SH , Hur CG , Kang HY , Kim D , Lee HH , Park KH , Park SH , Park HS , Lee HK , Oh TK , Kim JF
Ref : Nucleic Acids Research , 33 :7066 , 2005
Abstract : Harmful algal blooms, caused by rapid growth and accumulation of certain microalgae in the ocean, pose considerable impacts on marine environments, aquatic industries and even public health. Here, we present the 7.2-megabase genome of the marine bacterium Hahella chejuensis including genes responsible for the biosynthesis of a pigment which has the lytic activity against a red-tide dinoflagellate. H.chejuensis is the first sequenced species in the Oceanospiralles clade, and sequence analysis revealed its distant relationship to the Pseudomonas group. The genome was well equipped with genes for basic metabolic capabilities and contained a large number of genes involved in regulation or transport as well as with characteristics as a marine heterotroph. Sequence analysis also revealed a multitude of genes of functional equivalence or of possible foreign origin. Functions encoded in the genomic islands include biosynthesis of exopolysacchrides, toxins, polyketides or non-ribosomal peptides, iron utilization, motility, type III protein secretion and pigmentation. Molecular structure of the algicidal pigment, which was determined through LC-ESI-MS/MS and NMR analyses, indicated that it is prodigiosin. In conclusion, our work provides new insights into mitigating algal blooms in addition to genetic make-up, physiology, biotic interactions and biological roles in the community of a marine bacterium.
ESTHER : Jeong_2005_Nucleic.Acids.Res_33_7066
PubMedSearch : Jeong_2005_Nucleic.Acids.Res_33_7066
PubMedID: 16352867
Gene_locus related to this paper: hahch-q2s6v8 , hahch-q2s7u4 , hahch-q2s8m0 , hahch-q2s9b5 , hahch-q2s9n3 , hahch-q2s796 , hahch-q2s803 , hahch-q2s809 , hahch-q2s829 , hahch-q2sae5 , hahch-q2sav4 , hahch-q2sbd6 , hahch-q2sc65 , hahch-q2scc5 , hahch-q2sci6 , hahch-q2sct6 , hahch-q2scw7 , hahch-q2sdy2 , hahch-q2seh8 , hahch-q2seq6 , hahch-q2sfm2 , hahch-q2sfm4 , hahch-q2sfm9 , hahch-q2sfx3 , hahch-q2sgj4 , hahch-q2sgn6 , hahch-q2sgt0 , hahch-q2sgz8 , hahch-q2shj8 , hahch-q2shp0 , hahch-q2shq5 , hahch-q2shv0 , hahch-q2shv4 , hahch-q2shz6 , hahch-q2sic0 , hahch-q2sil6 , hahch-q2sj56 , hahch-q2sje1 , hahch-q2sje8 , hahch-q2skf9 , hahch-q2skg3 , hahch-q2skl5 , hahch-q2skv5 , hahch-q2sl80 , hahch-q2sll2 , hahch-q2slq4 , hahch-q2sls7 , hahch-q2sm17 , hahch-q2sn09 , hahch-q2sn54 , hahch-q2snn5 , hahch-q2snq6 , hahch-q2snw9 , hahch-q2spi5 , hahch-q2spk1 , hahch-q2spm8 , hahch-q2sq02 , hahch-q2sqg8 , hahch-q2sqn4 , hahch-q2sqx6 , hahch-q2sjs2

Title : DNA sequence and comparative analysis of chimpanzee chromosome 22 - Watanabe_2004_Nature_429_382
Author(s) : Watanabe H , Fujiyama A , Hattori M , Taylor TD , Toyoda A , Kuroki Y , Noguchi H , BenKahla A , Lehrach H , Sudbrak R , Kube M , Taenzer S , Galgoczy P , Platzer M , Scharfe M , Nordsiek G , Blocker H , Hellmann I , Khaitovich P , Paabo S , Reinhardt R , Zheng HJ , Zhang XL , Zhu GF , Wang BF , Fu G , Ren SX , Zhao GP , Chen Z , Lee YS , Cheong JE , Choi SH , Wu KM , Liu TT , Hsiao KJ , Tsai SF , Kim CG , S OO , Kitano T , Kohara Y , Saitou N , Park HS , Wang SY , Yaspo ML , Sakaki Y
Ref : Nature , 429 :382 , 2004
Abstract : Human-chimpanzee comparative genome research is essential for narrowing down genetic changes involved in the acquisition of unique human features, such as highly developed cognitive functions, bipedalism or the use of complex language. Here, we report the high-quality DNA sequence of 33.3 megabases of chimpanzee chromosome 22. By comparing the whole sequence with the human counterpart, chromosome 21, we found that 1.44% of the chromosome consists of single-base substitutions in addition to nearly 68,000 insertions or deletions. These differences are sufficient to generate changes in most of the proteins. Indeed, 83% of the 231 coding sequences, including functionally important genes, show differences at the amino acid sequence level. Furthermore, we demonstrate different expansion of particular subfamilies of retrotransposons between the lineages, suggesting different impacts of retrotranspositions on human and chimpanzee evolution. The genomic changes after speciation and their biological consequences seem more complex than originally hypothesized.
ESTHER : Watanabe_2004_Nature_429_382
PubMedSearch : Watanabe_2004_Nature_429_382
PubMedID: 15164055
Gene_locus related to this paper: pantr-a0a2j8lmv7

Title : Anti-hepatotoxic effects of Rosa rugosa root and its compound, rosamultin, in rats intoxicated with bromobenzene - Cheol_2004_J.Med.Food_7_436
Author(s) : Cheol Park J , Chul Kim S , Moon Hur J , Choi SH , Yeon Lee K , Won Choi J
Ref : J Med Food , 7 :436 , 2004
Abstract : The effects of a methanol extract of Rosa rugosa root and its triterpenoid glycoside, rosamultin, on hepatic lipid peroxidation and drug-metabolizing enzymes were investigated in rats treated with bromobenzene. The methanol extract of R. rugosa root reduced the activities of aminopyrine N-demethylase and aniline hydroxylase, which had been increased by bromobenzene, but rosamultin did not affect the activities of the two enzymes. Both the methanol extract and rosamultin restored the activity of epoxide hydrolase, which had also been decreased by bromobenzene. Hepatic glutathione concentrations were lowered and hepatic lipid peroxides were increased in rats intoxicated with bromobenzene. The hepatic lipid peroxidation induced by bromobenzene was prevented with the methanol extract and rosamultin. However, the decrease in glutathione was not altered by the methanol extract of R. rugosa. These results suggest that the extract of R. rugosa and its compound, rosamultin, may protect against bromobenzene-induced hepatotoxicity through, at least in part, enhanced activity of epoxide hydrolase. Antioxidant properties may contribute to the protection of R. rugosa against bromobenzene-induced hepatotoxicity.
ESTHER : Cheol_2004_J.Med.Food_7_436
PubMedSearch : Cheol_2004_J.Med.Food_7_436
PubMedID: 15671686

Title : Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11 - Park_2002_J.Neurosci.Res_70_484
Author(s) : Park CH , Choi SH , Koo JW , Seo JH , Kim HS , Jeong SJ , Suh YH
Ref : Journal of Neuroscience Research , 70 :484 , 2002
Abstract : We carried out this study to search a new active constituent that had cognitive enhancing activity and low side effects from natural source. We found that the extract of dried root of Polygala tenuifolia Willdenow (BT-11, 10 mg/kg, i.p.) could significantly reverse scopolamine-induced cognitive impairments in rat, using a passive avoidance and a water maze test. We also investigated the effects of BT-11 on neurotoxicity induced by glutamate (Glu) and toxic metabolites of amyloid precursor protein (APP) such as amyloid beta protein (A beta) and C-terminal fragment of APP (CT) in primary cultured neurons of rat. The pretreatment of BT-11 (0.5, 3, and 5 micro g/ml) significantly reduced cell death induced by Glu (1 mM), A beta (10 micro M) and CT105 (10 micro M) in a dose-dependent manner. In addition, BT-11 inhibited acetylcholinesterase (AChE) activity in a dose-dependent and non-competitive manner (IC(50) value; 263.7 micro g/ml). Our novel findings suggest the possibility that this extract may have some protective effects against neuronal death and cognitive impairments in Alzheimer's disease (AD), or other neurodegenerative diseases related to excitotoxicity and central cholinergic dysfunction.
ESTHER : Park_2002_J.Neurosci.Res_70_484
PubMedSearch : Park_2002_J.Neurosci.Res_70_484
PubMedID: 12391609

Title : Inhibition of lipopolysaccharide-induced I-kappaB degradation and tumor necrosis factor-alpha expression by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB): minor role in hepatic detoxifying enzyme expression - Kim_2000_Liver_20_319
Author(s) : Kim SG , Kim HJ , Choi SH , Ryu JY
Ref : Liver , 20 :319 , 2000
Abstract : AIMS/BACKGROUND: Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) is active against a variety of hepatotoxins and has been used as a curative agent for patients with acute and chronic viral hepatitis. Effects of DDB on the expression of xenobiotic-metabolizing enzymes and on nuclear factor-kappaB (NF-kappaB) activation and tumor necrosis factor-alpha (TNF-alpha) production by lipopolysaccharide (LPS), an endotoxin involved in inflammatory responses, were examined in rats and in RAW264.7 cells to investigate mechanistic aspects.
METHODS: Expression of hepatic cytochrome P450s, microsomal epoxide hydrolase and glutathione S-transferases was determined by immunoblot and Northern blot analyses. Activation of hepatic NF-kappaB and I-kappaBalpha degradation was assessed by gel mobility shift and immunoblot analyses, respectively. LPS-induced TNF-alpha expression was monitored in rats and in RAW264.7 cells by enzyme-linked immunosorbent assay and/or reverse transcription-polymerase chain reaction analysis.
RESULTS: DDB failed to alter the expression of hepatic cytochrome P450 1A and 2C11, microsomal epoxide hydrolase and glutathione S-transferases in rats with slight inhibition of P450 2E1 expression, but induced P450 2B1/2. Pretreatment of rats with DDB prevented LPS-induced hepatic I-kappaBalpha degradation and the resultant NF-kappaB activation, and inhibited the LPS-induced plasma TNF-alpha protein and hepatic TNF-alpha mRNA expression in a dose-dependent manner. LPS-induced I-kappaBalpha degradation and TNF-alpha production were also inhibited by DDB in RAW264.7 cells, which was consistent with the results in rats.
CONCLUSIONS: The present study demonstrated that DDB may inhibit inflammatory responses in association with reduction of NF-kappaB activation through prevention of I-kappaBalpha degradation and subsequent TNF-alpha production, but not with modulation of the detoxifying enzyme expression.
ESTHER : Kim_2000_Liver_20_319
PubMedSearch : Kim_2000_Liver_20_319
PubMedID: 10959811